| CASE REPORT |
|
| Year : 2021 | Volume
: 14
| Issue : 1 | Page : 52-55 |
|
|
Neovascularization of angle following trabeculectomy augmented with mitomycin-C
Wesam Shamseldin Shalaby1, Reza Razeghinejad2
1 Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA; Department of Ophthalmology, Tanta Medical School, Tanta University, Tanta, Gharbia, Egypt
2 Glaucoma Service, Wills Eye Hospital, Philadelphia, PA, USA
Correspondence Address:
Dr. Wesam Shamseldin Shalaby
840 Walnut Street, Suite 1140, Philadelphia, PA 19107
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ojo.OJO_71_2020
|
|
|
The purpose of this study was to report a case of neovascularization of angle (NVA) following trabeculectomy with mitomycin-c (MMC) in a patient with primary open-angle glaucoma. This case report describes a 68-year-old woman who developed NVA and hyphema 2 weeks following an uneventful trabeculectomy with MMC. Trabeculectomy may be associated with serious and vision-threatening complications such as hypotony, suprachoroidal hemorrhage, endophthalmitis, and bleb-related complications. However, neovascularization of the anterior segment is not a commonly reported complication. Neovascularization of the anterior segment is a rare postoperative complication that usually occurs following strabismus or retinal detachment surgeries. The underlying ischemic trigger for anterior segment neovascularization is usually a posterior segment pathology or carotid artery insufficiency. These causative factors were excluded in our patient by lack of any abnormal finding in fundus fluorescein angiography and carotid Doppler ultrasonography. The patient received three subconjunctival bevacizumab injections (1.25 mg/0.1 ml) with frequent topical steroids and showed marked regression of the neovessels. The bleb was functional, and intraocular pressure remained at low teen afterward. NVA following trabeculectomy without any posterior segment or carotid pathologies responded well to subconjunctival bevacizumab and topical steroids.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
